Provided by Tiger Trade Technology Pte. Ltd.

Biogen

222.15
-0.7400-0.33%
Post-market: 222.150.00000.00%19:49 EDT
Volume:1.30M
Turnover:291.04M
Market Cap:32.80B
PE:39.46
High:228.00
Open:222.93
Low:221.40
Close:222.89
52wk High:230.49
52wk Low:138.00
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.07
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.74
PE(LYR):25.27

Loading ...

Biogen - Serious Adverse Events Occurred in 3.4% of Participants During 52-Week Treatment Period

THOMSON REUTERS
·
Oct 02

Biogen - 33.7% of Crossover Participants Report Clear or Almost Clear Skin at Week 52

THOMSON REUTERS
·
Oct 02

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02

Biogen Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

Compass Pathways Names Kelley Boucher Chief People Officer

Reuters
·
Sep 30

Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (HRMY), BioNTech SE (BNTX) and Biogen (BIIB)

TIPRANKS
·
Sep 26

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22

Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB)

TIPRANKS
·
Sep 18

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 18

Biogen publishes results from adolescent subgroup of VALIANT study

TIPRANKS
·
Sep 18

Eisai, Biogen announce Leqembi Pen has been approved in Japan

TIPRANKS
·
Sep 16

US FDA Approves Scholar Rock's Muscle Weakness Drug

Reuters
·
Sep 12

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 11

Biogen Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

This Biotech Wins a Big FDA Approval. Why Wall Street is Shrugging.

Dow Jones
·
Sep 05

Correction: Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi

MT Newswires Live
·
Sep 04

Stoke Therapeutics, Biogen present long-term data on Zorevunersen

TIPRANKS
·
Sep 04

Stoke Therapeutics, Biogen Report 4-Year Open-Label Data for Dravet Drug Zorevunersen Showing Durable Seizure Reduction

Reuters
·
Sep 04

Stoke Therapeutics and Biogen Present Long-Term Clinical Data That Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16TH European Epilepsy Congress (Eec)

THOMSON REUTERS
·
Sep 04